Quantcast
Last updated on April 16, 2014 at 13:48 EDT

Latest Stent Stories

2013-07-22 12:26:01

TUSTIN, Calif., July 22, 2013 /PRNewswire/ -- MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced earlier last week that they successfully completed their first enrollment in a multi-center, prospective, pivotal U.S. clinical trial to demonstrate the safety and efficacy of its FRED(TM) flow diversion system (FRED(TM)-Flow Re-Direction Endoluminal Device) for treating intracranial aneurysms. Intracranial aneurysms are an abnormal, outward bulging of an artery...

2013-07-17 23:20:11

Over 2000 patients have been treated with innovative 14 French Endovascular Aortic Repair (EVAR) device. Santa Rosa, CA (PRWEB) July 17, 2013 TriVascular, Inc. announced today the initiation of a U.S. Post-Approval Study (PAS) of the Ovation Prime Abdominal Stent Graft System for the treatment of abdominal aortic aneurysms (AAA). The study’s national principal investigator will be Dr. Syed Hussain, Director of Vascular and Endovascular Surgery at OSF/HeartCare MidWest and Assistant...

2013-07-17 12:26:47

Importance of Coronary Artery Healing, Causes and Risk Factors of Delayed or Impaired Healing Are Focus of Website NEW YORK, July 17, 2013 /PRNewswire/ -- A new website, HeartVesselHealing.com, was launched today as an educational resource for patients and healthcare professionals regarding the risks associated with delayed arterial healing following coronary stent implantation. The website provides information about the importance of coronary artery healing following stent...

2013-07-15 23:16:40

Transparency Market Research Published new "Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 - 2016)" market research report to its report store. Browse the report; visit http://www.transparencymarketresearch.com/coronary-stents-market.html Albany, New York (PRWEB) July 15, 2013 According to Transparency Market Research “Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 – 2016)”Global Coronary Stents market...

2013-07-10 12:27:24

-- Enhanced Deliverability with New Stent Delivery System ABBOTT PARK, Ill., July 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the XIENCE Xpedition(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD), the most common form of heart disease.(i )XIENCE Xpedition is supported by the robust clinical evidence of the XIENCE family of drug eluting stents...

2013-07-10 10:21:08

Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries). The researchers identified 91 studies for inclusion in the review. "Percutaneous coronary intervention is commonly...

2013-07-03 08:25:27

BOSTON and TEL AVIV, Israel, July 3, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, announced that Alan Milinazzo, the Company's President and Chief Executive Officer, will present at the 8th Annual JMP Securities Healthcare Conference to be held July 9 & 10 in New York City. Mr. Milinazzo's presentation is scheduled to take place on Tuesday July 9 at 11:00 AM EDT. About Stenting and...

2013-06-11 12:28:17

- Trial to Study the Innovative "Dissolving" Heart Device Compared to Abbott's Market-Leading Drug Eluting Stents in Patients with Coronary Artery Disease in Japan ABBOTT PARK, Ill., June 11, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb(TM) Bioresorbable Vascular Scaffold (BVS) in patients with coronary artery disease (CAD), the most common form of heart disease.(1) The...

2013-05-30 12:27:33

NEW YORK, LONDON, BERLIN and PARIS, May 30, 2013 /PRNewswire/ -- The emerging Bioabsorbable Stent market [http://www.reportstack.com/product/100135/medipoint-bioabsorbable-stents-global-analysis-and-market-forecasts.html ] is steadily growing in the major markets in Europe (France, Germany, Italy, Spain and the UK), dominated by Abbott Vascular and Kyoto Medical Planning, with new entrants including Biotronik, REVA Medical and Elixir Medical Corporation. Coronary artery...

2013-05-27 04:20:27

Company Receives CE Mark for COMBO Dual Therapy Stent(TM); Introduces Product in Europe and Markets in Asia Pacific and Middle East Regions HONG KONG, May 27, 2013 /PRNewswire/ -- OrbusNeich today launched the world's first dual therapy stent - the COMBO Dual Therapy Stent - to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), the current standard of care for the treatment of coronary artery disease (CAD). The...


Latest Stent Reference Libraries

Interventional Radiology
2013-03-04 16:18:42

Interventional radiology (IR) is a special sub-operation under general radiology. It is used to find, diagnose and treat a disease in almost every body system. The process of interventional radiology is very noninvasive to help with the recovery and outcome of the procedure. It utilizes x-rays, CT, ultrasound, MRI, and other modes of imaging in order to direct tools in the body as well as a variety of catheters, narrow tubes, so that incisions can be minimalized. How it is Performed...

More Articles (1 articles) »